Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
The study addresses the question if a therapy with bendamustine plus rituximab is comparable (non inferior) with the well-tried combination of fludarabine plus rituximab with regard to event free survival (EFS) in recurrent low malignant Non-Hodgkin and mantle cell lymphomas.
Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma
DRUG: Bendamustine plus Rituximab|DRUG: Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
Event Free Survival, From date of randomization until the date of first documented progression, date of detection of a secondary malignancy or date of death from any cause, whichever came first. Minimum 1 year, Observation till event or death, minimum 1 year
Remission Rates, From date of randomization until the date of first documented progression, date of detection of a secondary malignancy or date of death from any cause, whichever came first. Minimum 1 year, Observation till event or death, minimum 1 year
The study addresses the question if a therapy with bendamustine plus rituximab is comparable (non inferior) with the well-tried combination of fludarabine plus rituximab with regard to event free survival (EFS) in recurrent low malignant Non-Hodgkin and mantle cell lymphomas.